News | Hypertension | July 15, 2020

Omron and Mount Sinai Health Collaborate to Monitor High-risk Patient Blood Pressure at Home

Technology ensures close connection between patient and physician for remote hypertension monitoring, including COVID-19 patients

VitalSight is a HIPAA-compliant, Medicare-reimbursable home blood pressure monitoring solution that generally comes at no cost to the patient, depending on their coverage. The kit typically includes a digital blood pressure monitor with cuff, weight scale and digital medication tracker, as well as a data hub.

July 15, 2020 – Omron Healthcare Inc. and Mount Sinai Health System, New York City’s largest academic medical system, have teamed to offer patients the new VitalSight home blood pressure monitoring solution. Mount Sinai recently rolled out the VitalSight program to support the needs of their patients with hypertension.

The effort to provide VitalSight to patients is led by Rob Fields, M.D., SVP and chief medical officer for population health at Mount Sinai, and a team of clinical pharmacists, who are responsible for the day-to-day management of the program and coordination with physicians to ensure that patients receive individualized care.  

“The ability to monitor patients at home during the pandemic – and on an ongoing basis – is critical. Our collaboration with Omron Healthcare helps make patients active participants in their own healthcare and extends the reach of clinicians, who receive a continuous stream of their patients’ real-time health data so that they can proactively intervene as necessary,” Fields  said. “Additionally, we are focusing first on our most vulnerable patients, who bear the consequences of disparities in care – in part, due to lack of technology access. This program requires no technology and comes at no cost for the device, with little-to-no cost for service.”

“We’re excited to collaborate with such a prestigious healthcare institution as Mount Sinai, who played an instrumental role in shaping the value of VitalSight from early in its development. Now, they are leading the way for patients to use VitalSight from the privacy of their home, while staying closely connected to their physician,” explained Omron Healthcare President and CEO Ranndy Kellogg. 

VitalSight is the newest addition to the line of Omron Healthcare home blood pressure monitors, which are among the top doctor and pharmacist recommended systems.[1,2] The VitalSight kit complements Mount Sinai’s commitment to remotely monitor patients as part of its recent telehealth initiative, especially as providers care for COVID-19 patients who are recovering at home. 

VitalSight is a HIPAA-compliant, Medicare-reimbursable home blood pressure monitoring solution that generally comes at no cost to the patient, depending on their coverage. The kit typically includes a digital blood pressure monitor with cuff, weight scale and digital medication tracker, as well as a data hub. Exact devices may vary based on what the physician deems appropriate for each patient’s hypertension monitoring needs. VitalSight directly links to a physician’s electronic medical record (EMR), and is compatible with leading systems. Patients measure their blood pressure, weigh themselves and continue to take their medication as ordered by their physician. Securely encrypted data is automatically sent to the doctor’s EMR in real time, where it’s stored for reference unless a health concern is detected, in which case the physician’s office is alerted.

For more information: www.omronhealthcare.com

References:
1. Frost & Sullivan Survey, Blood pressure clinician perception tracker surveys. 17 July 2019.

2. U.S. News Staff 2019, U.S. News & World Report. https://health.usnews.com/health-products/top-rec-blood-pressure-monitors-14, accessed 8 August 2019.
 

Related Content

Rates of burnout pre- and peak COVID-19 pandemic increased across all members of the cardiology care team and was particularly striking among cardiovascular team members, which researchers said may be because they were more likely at the bedside as patients were dying. Among all cardiovascular clinicians – cardiologists, physician assistants, nurse practitioners, nurses, pharmacists and imaging technologists – half provided direct care to patients with COVID-19. #COVID19 #ACCCOVID

Rates of burnout pre- and peak COVID-19 pandemic increased across all members of the cardiology care team and was particularly striking among cardiovascular team members, which researchers said may be because they were more likely at the bedside as patients were dying. Among all cardiovascular clinicians – cardiologists, physician assistants, nurse practitioners, nurses, pharmacists and imaging technologists – half provided direct care to patients with COVID-19, and yet one of five reported not having adequate personal protective equipment (PPE). Not surprisingly, the rate of burnout was higher in this group. Getty Images
 

News | Coronavirus (COVID-19) | June 07, 2021
June 7, 2021 — The COVID-19 pandemic has taken a significant toll on cardiovascular clinicians, many of whom provide
U.S. positive COVID test case data for 2020 through June 3, 2021, It shows four clear waves of spikes in U.S. COVID cases. Most of these appeared to be partly fueled by people gathering during the July 4, Halloween, Thanksgiving, Christmas, New Year's, Valentine's Day, and easter holidays. Source: John Hopkins University

U.S. positive COVID test case data for 2020 through June 3, 2021, It shows four clear waves of spikes in U.S. COVID cases. Most of these appeared to be partly fueled by people gathering during the July 4, Halloween, Thanksgiving, Christmas, New Year's, Valentine's Day, and easter holidays. Source: Johns Hopkins University

News | Coronavirus (COVID-19) | June 04, 2021 | By Dave Fornell, Editor
Vaccinations appear to to be helping reduce...
MRI scan of heart damaged by COVID, which can cause myocarditis, infarction and/or ischemia. Blue means reduced blood flow, orange is good blood flow. In this figure the inferior part of the heart shows dark blue, so the myocardial blood flow is very reduced. The angiogram shows the coronary artery which supplies the blood to this part of the heart is occluded. The three colored MRI images show different slices of the heart — the basal mid and apical slices. Image courtesy of European Heart Journal

MRI scan of heart damaged by COVID, which can cause myocarditis, infarction and/or ischemia. Blue means reduced blood flow, orange is good blood flow. In this figure the inferior part of the heart shows dark blue, so the myocardial blood flow is very reduced. The angiogram shows the coronary artery which supplies the blood to this part of the heart is occluded. The three colored MRI images show different slices of the heart — the basal mid and apical slices. Read more. Image courtesy of European Heart Journal

News | Coronavirus (COVID-19) | June 03, 2021
DAIC's sister radiology magazine Imaging Technology News (ITN) has created a photo gallery that sho
The WASE-COVID Study used the artificial intelligence automated echocardiogram reading software EchoGo-Core from Ultromics to evaluate ejection fraction and left ventricle longitudinal strain in COVID-19 patients to identify risk markers for mortality. The study also compared human vs. AI variability in assessing the exams. #ACC21 #ACC2021

The WASE-COVID Study used the artificial intelligence automated echocardiogram reading software EchoGo-Core from Ultromics to evaluate ejection fraction and left ventricle longitudinal strain in COVID-19 patients to identify risk markers for mortality. The study also compared human vs. AI variability in assessing the exams.

Feature | Coronavirus (COVID-19) | May 18, 2021
May 18, 2021 — Artificial intelligence (AI) derived heart measurements were able to predict...
Dapagliflozin did not significantly reduce organ failure or death in high-risk hospitalized COVID-19 patients in the DARE-19 trial results, presented at ACC.21. #ACC #ACC21 #ACC2021

Dapagliflozin did not significantly reduce organ failure or death in high-risk hospitalized COVID-19 patients in the DARE-19 trial results, presented at ACC.21.

News | Coronavirus (COVID-19) | May 18, 2021
May 18, 2021 — Dapagliflozin (Farxiga), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, did not significantly re
According to the CDC, if you are fully vaccinated you can start doing many things that you had stopped doing because of the pandemic. Infographic courtesy of the CDC.

According to the CDC, if you are fully vaccinated you can start doing many things that you had stopped doing because of the pandemic. Infographic courtesy of the CDC.

News | Coronavirus (COVID-19) | May 13, 2021
May 13, 2021 — The Centers for Disease Control and Prevention (CDC) just
Estimates of excess deaths, defined as the number of persons who have died from all causes, above the expected number of deaths for a given place and time, can provide a comprehensive account of mortality likely related to the COVID-19 pandemic, including deaths that are both directly and indirectly associated with COVID-19

Getty Images

News | Coronavirus (COVID-19) | May 13, 2021
May 13, 2021 — Estimates of excess deaths, defined as the number of persons who have died from all causes, above the
One third of patients will die who have COVID-19 (SARS-CoV-2) and suffer a ST-elevated myocardial infarction (STEMI), according to the latest, comprehensive data from The North American COVID-19 Myocardial Infarction (NACMI) Registry. The data was presented as a late-breaking study at the Society for Cardiovascular Angiography and Interventions (SCAI) 2021 Scientific Sessions. The study showed there was an alarming one-in-three patients dying with STEMI and COVID, compared to 4-in-100 #SCAI2021

The key slide from the SCAI 2021 NACMI late-breaking presentation showing the very high adverse rates for COVID STEMI heart attack patients (red) as compared to pre-pandemic STEMI patient controls (green).

Feature | Coronavirus (COVID-19) | May 03, 2021 | By Dave Fornell, Editor
May 3, 2021 – One third of patients will die who have COVID-19 (SARS-CoV-2) and suffer a ST-elevated myocardial infar
CDC and FDA Call for Pause on Janssen COVID-19 Vaccine Due to Rare Blood Clots #COVID19 #Janssen
Feature | Coronavirus (COVID-19) | April 13, 2021 | By Dave Fornell, Editor
(This story was updated May 7, 2021 in the last subheaded section)